The emerging multiple roles of nuclear Akt

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 12, 2012, Pages 2168-2178

  Martelli, Alberto M ^a,b   Tabellini, Giovanna ^c   Bressanin, Daniela ^a   Ognibene, Andrea ^b   Goto, Kaoru ^d   Cocco, Lucio ^a   Evangelisti, Camilla ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

Akt; Cell proliferation; Cell survival; MRNA export; Nucleus; Tumorigenesis

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; LIPID METABOLISM; MUSCLE CONTRACTILITY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; RNA PROCESSING; RNA SPLICING; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; UBIQUITINATION;

ANIMALS; CELL NUCLEUS; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84867283425     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.08.017     Document Type: Review

References (183)

1. Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an Sh2-like region. Science 1991, 254:274-277.
2. Marte B.M., Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 1997, 22:355-358.
3. Hanada M., Feng J.H., Hemmings B.A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim. Biophys. Acta 2004, 1697:3-16.
4. Masure S., Haefner B., Wesselink J.J., Hoefnagel E., Mortier E., Verhasselt P., Tuytelaars A., Gordon R., Richardson A. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur. J. Biochem. 1999, 265:353-360.
5. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010, 11:9-22.
6. Scheid M.P., Woodgett J.R. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546:108-112.
7. Bayascas J.R. PDK1: the major transducer of PI 3-kinase actions. Curr. Top. Microbiol. 2010, 346:9-29.
8. Raimondi C., Falasca M. Targeting PDK1 in cancer. Curr. Med. Chem. 2011, 18:2763-2769.
9. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
10. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3207-3212.
11. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC α but not S6K1. Dev. Cell 2006, 11:859-871.
12. Ruvolo P.P., Qui Y.H., Coombes K.R., Zhang N., Ruvolo V.R., Borthakur G., Konopleva M., Andreeff M., Kornblau S.M. Low expression of PP2A regulatory subunit B55 α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011, 25:1711-1717.
13. Eichhorn P.J.A., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795:1-15.
14. Warfel N.A., Newton A.C. Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J. Biol. Chem. 2012, 287:3610-3616.
15. Brognard J., Sierecki E., Gao T., Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 2007, 25:917-931.
16. Steelman L.S., Chappell W.H., Abrams S.L., Kempf R.C., Long J., Laidler P., Mijatovic S., Maksimovic-Ivanic D., Stivala F., Mazzarino M.C., Donia M., Fagone P., Malaponte G., Nicoletti F., Libra M., Milella M., Tafuri A., Bonati A., Basecke J., Cocco L., Evangelisti C., Martelli A.M., Montalto G., Cervello M., McCubrey J.A. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011, 3:192-222.
17. Hsieh A.C., Truitt M.L., Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br. J. Cancer 2011, 105:329-336.
18. Hafsi S., Pezzino F.M., Candido S., Ligresti G., Spandidos D.A., Soua Z., McCubrey J.A., Travali S., Libra M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance. Int. J. Oncol. 2012, 40:639-644.
19. Meuillet E.J. Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr. Med. Chem. 2011, 18:2727-2742.
20. Bartholomeusz C., Gonzalez-Angulo A.M. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:121-130.
21. Sale E.M., Sale G.J. Protein kinase B: signalling roles and therapeutic targeting. Cell. Mol. Life Sci. 2008, 65:113-127.
22. Blandino-Rosano M., Chen A.Y., Scheys J.O., Alejandro E.U., Gould A.P., Taranukha T., Elghazi L., Cras-Meneur C., Bernal-Mizrachi E. mTORC1 signaling and regulation of pancreatic β-cell mass. Cell Cycle 2012, 11:1892-1902.
23. Cheng G.Z., Zhang W.Z., Wang L.H. Regulation of cancer cell survival, migration, and invasion by twist: AKT2 comes to interplay. Cancer Res. 2008, 68:957-960.
24. Buttrick G.J., Wakefield J.G. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle 2008, 7:2621-2625.
25. Welsh G.L., Hers I., Berwick D.C., Dell G., Wherlock M., Birkin R., Leney S., Tavare J.M. Role of protein kinase B in insulin-regulated glucose uptake. Biochem. Soc. Trans. 2005, 33:346-349.
26. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001, 15:1406-1418.
27. Berwick D.C., Hers I., Heesom K.J., Moule S.K., Tavare J.M. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 2002, 277:33895-33900.
28. Wu M.Z., Falasca M., Blough E.R. Akt/protein kinase B in skeletal muscle physiology and pathology. J. Cell. Physiol. 2011, 226:29-36.
29. Chaanine A.H., Hajjar R.J. AKT signalling in the failing heart. Eur. J. Heart Fail. 2011, 13:825-829.
30. Keefe S.M., Cohen M.A., Brose M.S. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin. Cancer Res. 2010, 16:778-783.
31. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., Cappellini A., Ognibene A., McCubrey J.A. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim. Biophys. Acta 2010, 1803:991-1002.
32. Martelli A.M., Evangelisti C., Follo M.Y., Ramazzotti G., Fini M., Giardino R., Manzoli L., McCubrey J.A., Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr. Med. Chem. 2011, 18:2715-2726.
33. Polak R., Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012, 119:911-923.
34. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., Manzoli L., McCubrey J.A., Cocco L. Targeting the phosphatidylinositol 3-Kinase/Akt/Mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr. Med. Chem. 2007, 14:2009-2023.
35. Chiarini F., Fala F., Tazzari P.L., Ricci F., Astolfi A., Pession A., Pagliaro P., McCubrey J.A., Martelli A.M. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009, 69:3520-3528.
36. De Luca A., Maiello M.R., D'Alessio A., Pergameno M., Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 2012, 16:S17-S27.
37. Hers I., Vincent E.E., Tavare J.M. Akt signalling in health and disease. Cell. Signal. 2011, 23:1515-1527.
38. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., Basecke J., Stivala F., Donia M., Fagone P., Malaponte G., Mazzarino M.C., Nicoletti F., Libra M., Maksimovic-Ivanic D., Mijatovic S., Montalto G., Cervello M., Laidler P., Milella M., Tafuri A., Bonati A., Evangelisti C., Cocco L., Martelli A.M., McCubrey J.A. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2:135-164.
39. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
40. Tzivion G., Dobson M., Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 2011, 1813:1938-1945.
41. Kloet D.E.A., Burgering B.M.T. The PKB/FOXO switch in aging and cancer. Biochim. Biophys. Acta 2011, 1813:1926-1937.
42. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999, 96:857-868.
43. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21(Cip/WAF1) enhances protein stability of p21(Cip/WAF1) and promotes cell survival. J. Biol. Chem. 2002, 277:11352-11361.
44. Datta S.R., Dudek H., Tao X., Masters S., Fu H.A., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
45. Datta S.R., Ranger A.M., Lin M.Z., Sturgill J.F., Ma Y.C., Cowan C.W., Dikkes P., Korsmeyer S.J., Greenberg M.E. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev. Cell 2002, 3:631-643.
46. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E., Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updates 2007, 10:13-29.
47. Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 2001, 21:893-901.
48. Romashkova J.A., Makarov S.S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
49. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
50. Du K.Y., Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J. Biol. Chem. 1998, 273:32377-32379.
51. Caravatta L., Sancilio S., Di Giacomo V., Rana R., Cataldi A., Di Pietro R. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL. J. Cell. Physiol. 2008, 214:192-200.
52. Wang J.M., Chao J.R., Chen W.H., Kuo M.L., Yen J.J.Y., Yen H.F.Y. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 1999, 19:6195-6206.
53. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10:431-442.
54. Feng J.H., Tamaskovic R., Yang Z.Z., Brazil D.P., Merlo A., Hess D., Hemmings B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem. 2004, 279:35510-35517.
55. Pestell R.G., Albanese C., Reutens A.T., Segall J.E., Lee R.J., Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 1999, 20:501-534.
56. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001, 3:245-252.
57. Kip1 at threonine 157 and modulation of its cellular localization. Nat. Med. 2002, 8:1145-1152.
58. Diehl J.A., Cheng M.G., Roussel M.F., Sherr C.J. Glycogen synthase kinase 3 β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12:3499-3511.
59. Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-Myc proteolysis and subnuclear localization. J. Biol. Chem. 2003, 278:51606-51612.
60. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.
61. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway. Mol. Cell 2002, 10:151-162.
62. DeYoung M.P., Horak P., Sofer A., Sgroi D., Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22:239-251.
63. Jin H.O., Seo S.K., Kim Y.S., Woo S.H., Lee K.H., Yi J.Y., Lee S.J., Choe T.B., Lee J.H., An S., Hong S.I., Park I.C. TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1. Oncogene 2011, 30:3792-3801.
64. Wang H.T., Zhang Q.S., Wen Q., Zheng Y.X., Philip L., Jiang H., Lin J., Zheng W.H. Proline-rich Akt substrate of 40 kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell. Signal. 2012, 24:17-24.
65. Obata T., Yaffe M.B., Leparc G.G., Piro E.T., Maegawa H., Kashiwagi A., Kikkawa R., Cantley L.C. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem. 2000, 275:36108-36115.
66. Dubois F., Vandermoere F., Gernez A., Murphy J., Toth R., Chen S.A., Geraghty K.M., Morrice N.A., MacKintosh C. Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. Mol. Cell. Proteomics 2009, 8:2487-2499.
67. Martelli A.M., Evangelisti C., Chappell W., Abrams S.L., Basecke J., Stivala F., Donia M., Fagone P., Nicoletti F., Libra M., Ruvolo V., Ruvolo P., Kempf C.R., Steelman L.S., McCubrey J.A. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25:1064-1079.
68. Wilson K.L., Dawson S.C. Functional evolution of nuclear structure. J. Cell Biol. 2011, 195:171-181.
69. Hoelz A., Debler E.W., Blobel G. The structure of the nuclear pore complex. Annu. Rev. Biochem. 2011, 80:613-643.
70. D'Angelo M.A., Hetzer M.W. Structure, dynamics and function of nuclear pore complexes. Trends Cell Biol. 2008, 18:456-466.
71. Lusk C.P., Blobel G., King M.C. Highway to the inner nuclear membrane: rules for the road. Nat. Rev. Mol. Cell Biol. 2007, 8:414-420.
72. Kind J., van Steensel B. Genome-nuclear lamina interactions and gene regulation. Curr. Opin. Cell Biol. 2010, 22:320-325.
73. Cremer T., Cremer M. Chromosome territories. CSH Perspect. Biol. 2010, 2:a003889.
74. de Wit E., de Laat W. A decade of 3C technologies: insights into nuclear organization. Genes Dev. 2012, 26:11-24.
75. Geyer P.K., Vitalini M.W., Wallrath L.L. Nuclear organization: taking a position on gene expression. Curr. Opin. Cell Biol. 2011, 23:354-359.
76. Meldi L., Brickner J.H. Compartmentalization of the nucleus. Trends Cell Biol. 2011, 21:701-708.
77. Fakan S., van Driel R. The perichromatin region: a functional compartment in the nucleus that determines large-scale chromatin folding. Semin. Cell Dev. Biol. 2007, 18:676-681.
78. Dundr M., Misteli T. Biogenesis of nuclear bodies. CSH Perspect. Biol. 2010, 2:a000711.
79. Arden K.C., Biggs W.H. Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling. Arch. Biochem. Biophys. 2002, 403:292-298.
80. Huang W.C., Chen C.C. Akt-phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol. Cell. Biol. 2005, 25:6592-6602.
81. Meier R., Alessi D.R., Cron P., Andjelkovic M., Hemmings B.A. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bβ. J. Biol. Chem. 1997, 272:30491-30497.
82. Astoul E., Watton S., Cantrell D. The dynamics of protein kinase B regulation during B cell antigen receptor engagement. J. Cell Biol. 1999, 145:1511-1520.
83. Ouyang Y.B., Zhang X.H., He Q.P., Wang G.X., Siesjo B.K., Hu B.R. Differential phosphorylation at Ser473 and Thr308 of Akt-1 in rat brain following hypoglycemic coma. Brain Res. 2000, 876:191-195.
84. Mistafa O., Hogberg J., Stenius U. Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem. Biophys. Res. Commun. 2008, 365:131-136.
85. Leinninger G.M., Backus C., Uhler M.D., Lentz S.I., Feldman E.L. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J. 2004, 18:1544-1546.
86. Borgatti P., Martelli A.M., Tabellini G., Bellacosa A., Capitani S., Neri L.M. Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. J. Cell. Physiol. 2003, 196:79-88.
87. Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., Russo G., Tsichlis P., Croce C.M. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3028-3033.
88. Noguchi M., Ropars V., Roumestand C., Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J. 2007, 21:2273-2284.
89. Kunstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., Roumestand C., Stern M.H., Noguchi M. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol. Cell. Biol. 2002, 22:1513-1525.
90. Fiorenza M.T., Torcia S., Canterini S., Bevilacqua A., Narducci M.G., Ragone G., Croce C.M., Russo G., Mangia F. TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos. Cell Death Differ. 2008, 15:420-422.
91. Badve S., Collins N.R., Bhat-Nakshatri P., Turbin D., Leung S., Thorat M., Dunn S.E., Geistlinger T.R., Carroll J.S., Brown M., Bose S., Teitell M.A., Nakshatri H. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers potential clinical implications. Am. J. Pathol. 2010, 176:2139-2149.
92. Teitell M.A. The TCL1 family of oncoproteins: co-activators of transformation. Nat. Rev. Cancer 2005, 5:640-648.
93. Saji M., Vasko V., Kada F., Allbritton E.H., Burman K.D., Ringel M.D. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem. Biophys. Res. Commun. 2005, 332:167-173.
94. Xuan Nguyen T.L., Choi J.W., Lee S.B., Ye K., Woo S.D., Lee K.H., Ahn J.Y. Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells. Biochem. Biophys. Res. Commun. 2006, 349:789-798.
95. Neri L.M., Martelli A.M., Borgatti P., Colamussi M.L., Marchisio M., Capitani S. Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC-ζ translocation to the nucleus of NGF-treated PC12 cells. FASEB J. 1999, 13:2299-2310.
96. Neri L.M., Bortul R., Tabellini G., Borgatti P., Baldini G., Celeghini C., Capitani S., Martelli A.M. Erythropoictin-induced erythroid differentiation of K562 cells is accompanied by the nuclear translocation of phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol (3,4,5) trisphosphate. Cell. Signal. 2002, 14:21-29.
97. Scheid M.P., Parsons M., Woodgett J.R. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol. Cell. Biol. 2005, 25:2347-2363.
98. Kikani C.K., Dong L.Q., Liu F. "New"-clear functions of PDK1: beyond a master kinase in the cytosol?. J. Cell. Biochem. 2005, 96:1157-1162.
99. Liu J., Brown R.E. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of mTOR in aggressive histological variants. Mod. Pathol. 2011, 24:1553-1559.
100. Rosner M., Hengstschläger M. Detection of cytoplasmic and nuclear functions of mTOR by fractionation. Methods Mol. Biol. 2012, 821:105-124.
101. Vazquez-Martin A., Cufi S., Oliveras-Ferraros C., Menendez J.A. Raptor, a positive regulator subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). Cell Cycle 2011, 10:3140-3152.
102. Iadevaia V., Zhang Z., Jan E., Proud C.G. mTOR signaling regulates the processing of pre-rRNA in human cells. Nucleic Acids Res. 2012, 40:2527-2539.
103. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., Cron P., Cohen P., Lucocq J.M., Hemmings B.A. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 1997, 272:31515-31524.
104. Ananthanarayanan B., Ni Q., Zhang J. Signal propagation from membrane messengers to nuclear effectors revealed by reporters of phosphoinositide dynamics and Akt activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15081-15086.
105. Lim M.A., Kikani C.K., Wick M.J., Dong L.Q. Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14006-14011.
106. Rubio M., Avitabile D., Fischer K., Emmanuel G., Gude N., Miyamoto S., Mishra S., Schaefer E.M., Brown J.H., Sussman M.A. Cardioprotective stimuli mediate phosphoinositide 3-kinase and phosphoinositide dependent kinase 1 nuclear accumulation in cardiomyocytes. J. Mol. Cell. Cardiol. 2009, 47:96-103.
107. 1 phase in CHO cells. Cell Biol. Int. 2012, 36:357-365.
108. Ji M., Zhang Q., Ye J., Wang X., Yang W., Zhu D. Myostatin induces p300 degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway. Cell. Signal. 2008, 20:1452-1458.
109. Mistafa O., Ghalali A., Kadekar S., Hogberg J., Stenius U. Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J. Biol. Chem. 2010, 285:27900-27910.
110. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
111. Cayrol C., Knibiehler M., Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998, 16:311-320.
112. Ando T., Kawabe T., Ohara H., Ducommun B., Itoh M., Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem. 2001, 276:42971-42977.
113. Ye Z.W., Ghalali A., Hogberg J., Stenius U. Silencing p110β prevents rapid depletion of nuclear pAkt. Biochem. Biophys. Res. Commun. 2011, 415:613-618.
114. Marques M., Kumar A., Poveda A.M., Zuluaga S., Hernandez C., Jackson S., Pasero P., Carrera A.C. Specific function of phosphoinositide 3-kinase β in the control of DNA replication. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7525-7530.
115. Vantini G., Skaper S.D. Neurotrophic factors - from physiology to pharmacology. Pharmacol. Res. 1992, 26:1-15.
116. Ebendal T. Function and evolution in the NGF family and its receptors. J. Neurosci. Res. 1992, 32:461-470.
117. Liu X.S., Zou H., Slaughter C., Wang X.D. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997, 89:175-184.
118. Ahn J.Y., Rong R., Liu X.S., Ye K.Q. PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J. 2004, 23:3995-4006.
119. Sahara S., Aoto M., Eguchi Y., Imamoto N., Yoneda Y., Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999, 401:168-173.
120. Hu Y., Liu Z., Yang S.J., Ye K. Acinus-provoked protein kinase C δ isoform activation is essential for apoptotic chromatin condensation. Cell Death Differ. 2007, 14:2035-2046.
121. Hu Y.X., Yao J., Liu Z.X., Liu X., Fu H., Ye K.Q. Akt phosphorylates acinus and inhibits its proteolytic cleavage, preventing chromatin condensation. EMBO J. 2005, 24:3543-3554.
122. Hervy M., Hoffman L., Beckerle M.C. From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr. Opin. Cell Biol. 2006, 18:524-532.
123. Chan C.B., Liu X., Tang X., Fu H., Ye K. Akt phosphorylation of zyxin mediates its interaction with acinus-S and prevents acinus-triggered chromatin condensation. Cell Death Differ. 2007, 14:1688-1699.
124. Yoo J.Y., Wang X.W., Rishi A.K., Lessor T., Xia X.M., Gustafson T.A., Hamburger A.W. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br. J. Cancer 2000, 82:683-690.
125. Liu Z., Ahn J.Y., Liu X., Ye K. Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10917-10922.
126. Ahn J.Y., Liu X., Liu Z.X., Pereira L., Cheng D.M., Peng J.M., Wade P.A., Hamburger A.W., Ye K.Q. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J. 2006, 25:2083-2095.
127. Liu Z., Liu X., Nakayama K.I., Nakayama K., Ye K. Protein kinase C-δ phosphorylates Ebp1 and prevents its proteolytic degradation, enhancing cell survival. J. Neurochem. 2007, 100:1278-1288.
128. Colombo E., Alcalay M., Pelicci P.G. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011, 30:2595-2609.
129. Falini B., Gionfriddo I., Cecchetti F., Ballanti S., Pettirossi V., Martelli M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood Rev. 2011, 25:247-254.
130. Lee S.B., Nguyen T.L.X., Choi J.W., Lee K.H., Cho S.W., Liu Z.X., Ye K.Q., Bae S.S., Ahn J.Y. Nuclear At interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16584-16589.
131. Ahn J.Y., Liu X., Cheng D., Peng J., Chan P.K., Wade P.A., Ye K. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol. Cell 2005, 18:435-445.
132. Widlak P., Garrard W.T. Roles of the major apoptotic nuclease-DNA fragmentation factor-in biology and disease. Cell. Mol. Life Sci. 2009, 66:263-274.
133. Shah A.M., Mann D.L. Heart failure 1. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011, 378:704-712.
134. Aronson D., Krum H. Novel therapies in acute and chronic heart failure. Pharmacol. Ther. 2012, 135:1-17.
135. Tsujita Y., Muraski J., Shiraishi I., Kato T., Kajstura J., Anversa P., Sussman M.A. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11946-11951.
136. Shiraishi I., Melendez J., Ahn Y., Skavdahl M., Murphy E., Welch S., Schaefer E., Walsh K., Rosenzweig A., Torella D., Nurzynska D., Kajstura J., Leri A., Anversa P., Sussman M.A. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 2004, 94:884-891.
137. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., Liao R.L., Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 2002, 277:22896-22901.
138. Rota M., Boni A., Urbanek K., Padin-Iruegas M.E., Kajstura T.J., Fiore G., Kubo H., Sonnenblick E.H., Musso E., Houser S.R., Leri A., Sussman M.A., Anversa P. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 2005, 97:1332-1341.
139. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 2003, 4:566-577.
140. Camper-Kirby D., Welch S., Walker A., Shiraishi I., Setchell K.D., Schaefer E., Kajstura J., Anversa P., Sussman M.A. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ. Res. 2001, 88:1020-1027.
141. Murphy E., Steenbergen C. Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail. Rev. 2007, 12:293-300.
142. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J. Cardiol. 2010, 56:262-270.
143. Kato T., Muraski J., Chen Y., Tsujita Y., Wall J., Glembotski C.C., Schaefer E., Beckerle M., Sussman M.A. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J. Clin. Invest. 2005, 115:2716-2730.
144. Valerie K., Yacoub A., Hagan M.P., Curiel D.T., Fisher P.B., Grant S., Dent P. Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 2007, 6:789-801.
145. Bozulic L., Hemmings B.A. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 2009, 21:256-261.
146. Xu Y., Price B.D. Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle 2011, 10:261-267.
147. Hill R., Lee P.W. The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet?. Cell Cycle 2010, 9:3460-3469.
148. Bozulic L., Surucu B., Hynx D., Hemmings B.A. PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 2008, 30:203-213.
149. Thompson L.H. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat. Res. 2012, 751:158-246.
150. Fraser M., Harding S.M., Zhao H., Coackley C., Durocher D., Bristow R.G. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011, 10:2218-2232.
151. Stracker T.H., Petrini J.H. The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 2011, 12:90-103.
152. Bekker-Jensen S., Mailand N. The ubiquitin- and SUMO-dependent signaling response to DNA double-strand breaks. FEBS Lett. 2011, 585:2914-2919.
153. Viniegra J.G., Martinez N., Modirassari P., Hernandez Losa J., Parada Cobo C., Sanchez-Arevalo Lobo V.J., Aceves Luquero C.I., Alvarez-Vallina L., Ramon y Cajal S., Rojas J.M., Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 2005, 280:4029-4036.
154. Reed R., Magni K. A new view of mRNA export: separating the wheat from the chaff. Nat. Cell Biol. 2001, 3:E201-E204.
155. Zhou Z., Luo M.J., Straesser K., Katahira J., Hurt E., Reed R. The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature 2000, 407:401-405.
156. Okada M., Jang S.W., Ye K. Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8649-8654.
157. Valverde A.M., Benito M., Lorenzo M. The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance. Acta Physiol. Scand. 2005, 183:59-73.
158. Maiuri T., Ho J., Stambolic V. Regulation of adipocyte differentiation by distinct subcellular pools of protein kinase B (PKB/Akt). J. Biol. Chem. 2010, 285:15038-15047.
159. Abdelwahid E., Siminiak T., Guarita-Souza L.C., Teixeira de Carvalho K.A., Gallo P., Shim W., Condorelli G. Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications. Curr. Cardiol. Rev. 2011, 7:201-212.
160. Unno K., Jain M., Liao R. Cardiac side population cells: moving toward the center stage in cardiac regeneration. Circ. Res. 2012, 110:1355-1363.
161. Fischer K.M., Cottage C.T., Wu W., Din S., Gude N.A., Avitabile D., Quijada P., Collins B.L., Fransioli J., Sussman M.A. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009, 120:2077-2087.
162. Fischer K.M., Din S., Gude N., Konstandin M.H., Wu W.T., Quijada P., Sussman M.A. Cardiac progenitor cell commitment is inhibited by nuclear Akt expression. Circ. Res. 2011, 108:960-970.
163. Lee S.H., Kim H.S., Park W.S., Kim S.Y., Lee K.Y., Kim S.H., Lee J.Y., Yoo N.J. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002, 110:587-592.
164. Nicholson K.M., Streuli C.H., Anderson N.G. Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res. Treat. 2003, 81:117-128.
165. Van de Sande T., Roskams T., Lerut E., Joniau S., Van Poppel H., Verhoeven G., Swinnen J.V. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol. 2005, 206:214-219.
166. Vasko V., Saji M., Hardy E., Kruhlak M., Larin A., Savchenko V., Miyakawa M., Isozaki O., Murakami H., Tsushima T., Burman K.D., De Micco C., Ringel M.D. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 2004, 41:161-170.
167. Kip1 and control of cyclin D-1 expression. Leukemia 2003, 17:2157-2167.
168. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., Serve H. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005, 65:9643-9650.
169. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
170. Carracedo A., Ito K., Pandolfi P.P. The nuclear bodies inside out: PML conquers the cytoplasm. Curr. Opin. Cell Biol. 2011, 23:360-366.
171. 3. Trends Mol. Med. 2012, 18:36-42.
172. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J., Verbel D.A., Cordon-Cardo C., Pandolfi P.P. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 2004, 96:269-279.
173. Sarker D., Reid A.H., Yap T.A., de Bono J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15:4799-4805.
174. Miraglia E., Hogberg J., Stenius U. Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int. J. Oncol. 2012, 40:867-875.
175. Papadopoulos G., Delakas D., Nakopoulou L., Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur. J. Cancer 2011, 47:819-830.
176. Jacobs R.J., Kodach L.L., Hardwick J.C. The potential of statins for individualized colorectal cancer chemoprevention. Curr. Drug Targets 2011, 12:1903-1908.
177. Montironi R., Mazzuccheli R., Scarpelli M., Lopez-Beltran A., Fellegara G., Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int. 2005, 95:1146-1152.
178. Giudice F.S., Dal Vechio A.M.D., Abrahao A.C., Sperandio F.F., Pinto D.D. Different expression patterns of pAkt, NF-κB and cyclin D1 proteins during the invasion process of head and neck squamous cell carcinoma: an in vitro approach. J. Oral Pathol. Med. 2011, 40:405-411.
179. Suzuki Y., Shirai K., Oka K., Mobaraki A., Yoshida Y., Noda S., Okamoto M., Suzuki Y., Itoh J., Itoh H., Ishiuchi S., Nakano T. Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J. Radiat. Res. 2010, 51:343-348.
180. Cenni V., Bertacchini J., Beretti F., Lattanzi G., Bavelloni A., Riccio M., Ruzzene M., Marin O., Arrigoni G., Parnaik V., Wehnert M., Maraldi N.M., de Pol A., Cocco L., Marmiroli S. Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. J. Proteome Res. 2008, 7:4727-4735.
181. Franke T.F. Intracellular signaling by Akt: bound to be specific. Sci. Signal. 2008, 1:e29.
182. Sussman M.A., Volkers M., Fischer K., Bailey B., Cottage C.T., Din S., Gude N., Avitabile D., Alvarez R., Sundararaman B., Quijada P., Mason M., Konstandin M.H., Malhowski A., Cheng Z., Khan M., McGregor M. Myocardial AKT: the omnipresent nexus. Physiol. Rev. 2011, 91:1023-1070.
183. Tan S., Ng Y., James D.E. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem. J. 2011, 435:539-544.